Shan-Shan Du
Overview
Explore the profile of Shan-Shan Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Q, Jia S, Chi Q, Jin L, Chen X, Li J, et al.
Bioorg Chem
. 2025 Mar;
159:108344.
PMID: 40086188
Natural cytotoxic peptides (NCPs) are emerging sources of novel anticancer chemotherapeutics. Especially, Melittin, which is the major component of bee venom and the first-in-class NCP, has been considered as a...
2.
Chen X, Cui S, Chen Y, Wang C, Liu Q, Qi Y, et al.
Mol Pharm
. 2025 Feb;
22(3):1449-1461.
PMID: 39913295
The first-in-class oncolytic peptide LTX-315 has exhibited positive anticancer responses in multiple phase I/II clinical trials. Nevertheless, the linear peptide LTX-315 suffers from poor proteolytic stability and undesired toxicity, especially...
3.
Li Y, Fang C, Wang S, Chen X, Li Y, Liu Q, et al.
Bioorg Med Chem
. 2024 Aug;
111:117869.
PMID: 39126834
Recently, the sortilin receptor (SORT1) was found to be preferentially over-expressed on the surface of many cancer cells, which makes SORT1 a novel anticancer target. The SORT1 binding proprietary peptide...
4.
Zhao Y, Du S, Zhao C, Li T, Tong S, Zhao L
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000589
Mitogen-activated protein kinase kinase 1 (MAPK kinase 1, MEK1) is a key kinase in the mitogen-activated protein kinase (MAPK) signaling pathway. MEK1 mutations have been reported to lead to abnormal...
5.
Song M, Liu Q, Yao J, Wang Y, Ma Y, Xu H, et al.
Bioorg Med Chem
. 2024 May;
107:117760.
PMID: 38762978
Oncolytic peptides represented potential novel candidates for anticancer treatments especially drug-resistant cancer cell lines. One of the most promising and extensively studied is LTX-315, which is considered as the first...
6.
Xu H, Fu X, Bao Y, Zhu S, Xu Z, Song M, et al.
Bioorg Chem
. 2024 Apr;
147:107356.
PMID: 38604021
Developing "turn on" fluorescent probes was desirable for the detection of the effective anticoagulant agent heparin in clinical applications. Through combining the aggregation induced emission (AIE) fluorogen tetraphenylethene (TPE) and...
7.
Fu X, Yin H, Chen X, Yao J, Ma Y, Song M, et al.
J Med Chem
. 2024 Jan;
67(5):3885-3908.
PMID: 38278140
Oncolytic peptides represent promising novel candidates for anticancer treatments. In our efforts to develop oncolytic peptides possessing both high protease stability and durable anticancer efficiency, three rounds of optimization were...
8.
Yin H, Fu X, Gao H, Ma Y, Yao J, Du S, et al.
Bioorg Chem
. 2023 Jun;
138:106674.
PMID: 37331169
Nitrogen mustards (NMs) are an important class of chemotherapeutic drugs and have been widely employed for the treatment of various cancers. However, due to the high reactivity of nitrogen mustard,...
9.
Chi Q, Jia S, Yin H, Wang L, Fu X, Ma Y, et al.
Bioorg Chem
. 2023 Mar;
134:106451.
PMID: 36907048
Cytotoxic peptides derived from spider venoms have been considered as promising candidates for anticancer treatment. The novel cell penetrating peptide LVTX-8, which is a 25-residue amphipathic α-helical peptide isolated from...
10.
Yin H, Fu X, Gao H, Gao H, Ma Y, Chen X, et al.
Front Oncol
. 2023 Jan;
12:1028600.
PMID: 36713538
Liver cancer is the third leading cause of cancer-associated mortality globally, and >830,000 patients with liver cancer undergoing treatment succumbed to the disease in 2020, which indicates the urgent need...